Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men - Full Text View - Primary Outcome Measures: Number of documented incident HIV infections in Steps 1 and 2 [ Time Frame: Measured through participant's last study visit, up to 4.5 years after study entry ] [ Designated as safety issue: Yes ] Number of Grade 2 or higher clinical and laboratory adverse events [ Time Frame: Measured through participant's last study visit, up to 4.5 years after study entry ] [ Designated as safety issue: Yes ] The purpose of this study is to evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
This study will enroll HIV-uninfected MSM and TGW at risk for acquiring HIV infection. Participants will remain in the study between 1.5 years to 4.5 years, depending on when they enroll in the study. This study will take place in three steps. Mobile.aidsmap. A case report of a man in Toronto who became infected with a multi-drug-resistant strain of HIV despite apparently very consistent adherence to PrEP was presented at the CROI 2016 conference in Boston today.
Dr David Knox, a doctor at Toronto’s Maple Leaf Medical clinic, said the patient was a 43-year-old gay man who had been on PrEP for two years. He had an HIV-positive partner who was undetectable on antiretroviral therapy, but also had casual sex contacts involving the risk of HIV exposure. He was a regular attender at the clinic and tested for HIV on average every three months. No New HIV Infections in San Francisco Community PrEP Clinic. December 17, 2015, Emily Newman A trailblazing pre-exposure prophylaxis (PrEP) program by the San Francisco AIDS Foundation sexual health center Magnet was lauded at the 2015 HIV Prevention Conference.
The PrEP health program began as a pilot program in November, 2014 and will continue to expand when it moves into a new health and wellness center, Strut, in San Francisco’s Castro neighborhood. In early December, Magnet director Steve Gibson, MSW, shared lessons learned about the PrEP health program—which has seen no new HIV infections—at the conference in Atlanta, Georgia.
Adding vitamin D and calcium to a new HIV regimen curbs bone loss in the hip. By Alan McCord, Director of Education In a presentation at the 2014 CROI (Conference on Retroviruses and Opportunistic Infections) in Boston, taking high-dose vitamin D and calcium every day reduced the loss of hip bone mass in people who started on a regimen of efavirenz (Sustiva) + tenofovir/emtricitabine (Truvada).
Studies have shown that bone mineral density, or BMD, is reduced 2–6% in people who start an HIV regimen. PrEP Flow Chart. PrEP (Pre-Exposure Prophylaxis) NEW!
PrEP Flow Chart: This health care tool can help consumers and navigators with working through the process for finding a clinician, getting a prescription and covering the costs of PrEP. It’s laid out on a legal-sized sheet of paper, so feel free to print it on a desktop printer. . ( April/May #195 : Against All Odds - by Trenton Straube. PrEP - Benjamin RyanJournalist. The Danger in Comparing the HIV-Prevention Pill to Condoms. On Monday, August 3, I tested positive for HIV.
That night, I sat on the sofa in my friend’s high-rise apartment in downtown Miami, peering down at the grainy, sodium-vapor-lit sprawl. I related the story of an older friend who’d tried to console me by saying HIV-positive people stay healthy. The Questions About PrEP. Maybe you’re not completely sold on this new HIV prevention strategy.
You think it’s a hard pill to swallow and not all it’s cracked up to be. Here are the most common questions we’ve heard so far about PrEP: Hitting Bottom: Finding My Comfort With Sex Without Condoms. The World Health Organization’s recommendation that HIV negative gay men consider using PrEP has set off another dramatic maelstrom of controversy in the HIV prevention world.
Immediately, these new guidelines were distorted in media articles claiming all gay men “should” get on medications. My PrEP Facts Facebook Group immediately filled up with angry debates about who “should” take PrEP, who “should not”, whether it’s 92% or 99% effective, the evils of Big Pharma, upsets that PrEP doesn’t solve global warming or world hunger, and a general tone of hostility and attack. All I could do was hopelessly witness the shredding and think to myself, “All this arguing about butt sex? Daily Pill Can Prevent HIV. Preexposure prophylaxis (PrEP) is a medicine taken daily that can be used to prevent getting HIV.
PrEP is for people without HIV who are at very high risk for getting it from sex or injection drug use. People at high risk who should be offered PrEP include about 1 in 4 sexually active gay and bisexual men*, 1 in 5 people who inject drugs, and 1 in 200 sexually active heterosexual adults. When taken every day, PrEP is safe and highly effective in preventing HIV infection. PrEP is even more effective if it is combined with other ways to prevent new HIV infections like condom use, drug abuse treatment, and treatment for people living with HIV to reduce the chance of passing the virus to others. Many people who can benefit from PrEP aren't taking it.
Dr. Robert Grant: What Does Ipergay Tell Us About PrEP and ‘Seasons of Risk’? March 12, 2015, Emily Newman Much-anticipated efficacy results from a French study of intermittent PrEP were announced at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) at the end of February.
Although PrEP experts do not have enough information from this relatively small study of men to advise or recommend intermittent PrEP use, Ipergay does add to clinical knowledge about one important issue: how to stop using PrEP if it’s no longer needed. Dr. Robert Grant (photo: Liz Highleyman) Robert Grant, MD, of the Gladstone Institutes, the University of California at San Francisco and chief medical officer of San Francisco AIDS Foundation, is excited to discuss the implications of the Ipergay study, which he says will be even more exciting and relevant when the discussion includes informed PrEP users who are ultimately in charge of how PrEP is used. PrEP demonstration project: Modest bone density loss observed among young men. November 2, 2015, Liz Highleyman Most young men participating in a pre-exposure prophylaxis (PrEP) demonstration project saw a small but significant amount of bone loss after starting Truvada, researchers reported at the 15th European AIDS Conference last week in Barcelona.
Men who had the most highly protective levels of tenofovir in their blood, consistent with at least four doses per week, saw the largest decreases in bone density. “Although the BMD losses were generally modest [in this study], their occurrence before attainment of peak bone mass in young men who already have low bone mass may increase their risk of fragility in adulthood,” the researchers said. Tenofovir—one of the two drugs in the Truvada combination pill—was approved in 2001 and is one of the most widely used antiretrovirals for HIV treatment.
Print Rebate Welcome. Welcome to McKesson's Patient Rebate Online Portal! McKesson Patient Relationship Solutions is pleased to provide you with this fast, reliable means to obtain patient savings. It is designed to assist you in obtaining a refund for the discount amount you paid when you presented your co-pay card. After answering a few simple questions to validate eligibility, you will be able to download your personalized form which, along with a label and receipt, can be mailed back to McKesson for reimbursement. In most cases, checks are issued within 2-4 weeks of eligibility verification. We aim to make this process as simple as possible. PrEP: Your Burning Questions Answered. April 17, 2014, Megan Canon, MPH Dr. Albert Liu We know people have a lot of questions and concerns around PrEP. We enlisted Albert Liu, MD, MPH, from Bridge HIV at the San Francisco Department of Public Health, to answer common PrEP questions we’ve heard and help sort out what we know and what we don’t know about this new HIV prevention strategy.
What are the side effects from Truvada for PrEP? Truvada is a safe and well-tolerated drug. Here’s What We Actually Know About The Pill That Prevents HIV. Co-Pay Assistance. If you’re concerned about how you will pay for your HIV therapy, start by talking to your healthcare provider. He or she may be able to help you apply for assistance. If you have insurance Gilead HIV Co-pay Assistance Coupon Card. Side Effects. What is TRUVADA? TRUVADA is a prescription medicine used in 2 different ways: to treat HIV-1 infection in adults and teenagers (12 and older).
Huffingtonpost. Truvada prevents HIV infection in high-risk individuals! A clinical success built on animal research. In the past two weeks we’ve learned of a major advance in ongoing efforts to halt the spread of HIV, two separate clinical studies have reported that a daily regimen of a pill called Truvada as a pre-exposure prophylaxis (PrEP) is highly effective in preventing infection in high risk groups.
This success is a result not just of the dedication of the clinicians who conducted these trials, but also of a series of pivotal studies conducted in non-human primates more than a decade ago that laid the scientific foundations for them. Insight Into HIV Transmission Risk When the Viral Load Is Undetectable and No Condom Is Used - Resource Center on Keeping Up With Your HIV Meds. The sexual transmission of HIV occurs after an exposure to fluids that contain HIV, such as semen and fluids from the vagina and rectum.
The amount of virus in these fluids (also known as viral load) is the most important factor that determines whether an exposure to HIV will lead to infection. Research shows that a higher viral load increases the risk of HIV transmission and that a lower viral load decreases the risk. The viral load in the blood of a person living with HIV is measured regularly to monitor the success of antiretroviral therapy (also called ART). Successful ART can reduce the viral load in the blood and other bodily fluids to undetectable levels, which can reduce the risk of sexual transmission. ART therefore represents an important new HIV prevention tool, which also has the potential to reduce the guilt, blame and anxiety associated with the possibility of transmitting HIV to a partner.
Gaps in the Evidence Advertisement The PARTNER Study Results. HIV Basics. The Case for PrEP, or How I Learned to Stop Worrying and Love HIV-Positive Guys. Levi Hastings The pills are sky blue. Mobile.aidsmap. IRMA. Does Taking PrEP Encourage Risky Behavior? After 2.5 Years, No One in Large SF PrEP Group Contracts HIV - by Benjamin Ryan. HIV-preventing drug holds up under study - SFGate. UNC researchers: Drug cocktails can stop sexual transmission of HIV. Here’s What We Actually Know About The Pill That Prevents HIV. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States.
HIV Basics. To Prevent HIV Infection, Couples Try Testing Together. Putting a number on it: The risk from an exposure to HIV. Partners PrEP: Up to 90% Fewer Infections in Mixed-Status Hetero Couples - by Tim Horn. Mobile.aidsmap.